Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer
| Autor: | Beatrice Casini, Emilio Bria, Claudio Botti, Francesco Facciolo, Michele Milella, Maria Grazia Diodoro, Francesco Cognetti, M. Mottolese, F.L. Cecere, Isabella Sperduti, Flavia Novelli, P. Visca, Raffaele Perrone-Donnorso |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Oncology Cytoplasm medicine.medical_specialty Pathology Lung Neoplasms Survivin Positive survivin Inhibitor of Apoptosis Proteins Carcinoma Non-Small-Cell Lung Internal medicine Survivin Biomarkers Tumor Carcinoma medicine Humans Lung cancer neoplasms Aged Neoplasm Staging Retrospective Studies Tumor marker Cell Nucleus business.industry Hazard ratio non-small-cell lung cancer Prognosis Cancer General Medicine Middle Aged medicine.disease Neoplasm Proteins Immunohistochemistry Female Surgery business Microtubule-Associated Proteins |
| Zdroj: | European Journal of Surgical Oncology (EJSO). 34:593-598 |
| ISSN: | 0748-7983 |
| Popis: | Aim Survivin is a member of the inhibitors of apoptosis (IAP) gene family that acts through pathways different from those involving the bcl-2 family. Largely undetectable in normal adult tissues, survivin is deregulated in most human cancers including non-small-cell lung cancer (NSCLC) and may represent a tumor marker with prognostic and therapeutic implications. Aim of our study was to determine the prognostic role of survivin as an apoptosis-related biomarker in a series of resected NSCLC patients. Methods A retrospective series of resected NSCLC patients were retrieved from the files of the Regina Elena National Cancer Institute. Survivin was detected by immunohistochemistry (IHC) using a polyclonal antibody. Survivin displayed two kinds of immunoreactivity: (i) a diffuse cytoplasmic staining and (ii) a distinct nuclear staining. A score-scale to distinguish positive (score 1–2) vs. negative (score 0) pattern was applied. Clinical and biological (nuclear and cytoplasmic survivin staining) covariables were screened for a prognostic relationship with overall survival (OS) and disease-free survival (DFS) into the univariate and multivariate analyses. Results Data referring to 116 NSCLC patients who underwent surgery for stage I–IIIA NSCLC were collected. Multivariate analyses identified tumor size, nodal status and nuclear, but not cytoplasmic, expression of survivin as significant independent predictors of OS, with a hazard ratio of 2.40 (95% CI 1.44, 3.99, p =0.001), 2.03 (95% CI 1.26, 3.26, p =0.003) and 1.83 (95% CI 1.01, 3.30, p =0.044), respectively. Median OS for nuclear survivin positive (score 1–2) and negative (score 0) patients were 23 months (95% CI 15, 31) and 36 months (95% CI 1, 76), respectively ( p =0.01); five-year survival for score 1–2 and score 0 patients were 20% and 44.5%, respectively. Conversely, no significant impact on survival is found when patients are stratified according to cytoplasmic survivin expression. Conclusions Data presented herein open the issue that prognosis of stage I–IIIA NSCLC can be linked to the cellular pattern of distribution of survivin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect